OTCMKTS:SWTUY SWEDISH ORPHAN/S (SWTUY) Stock Price, News & Analysis $24.38 -0.29 (-1.18%) As of 04/9/2019 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About SWEDISH ORPHAN/S Stock (OTCMKTS:SWTUY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SWEDISH ORPHAN/S alerts:Sign Up Key Stats Today's Range$24.38▼$24.3850-Day Range$24.38▼$24.3852-Week Range$18.50▼$31.96Volume200 shsAverage Volume1,665 shsMarket Capitalization$6.64 billionP/E Ratio48.76Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSwedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.Read More… Receive SWTUY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SWEDISH ORPHAN/S and its competitors with MarketBeat's FREE daily newsletter. Email Address SWTUY Stock News HeadlinesSwedish Orphan Biovitrum AB: Sobi and Apellis: Aspaveli/Empaveli Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney DiseasesJune 6, 2025 | finanznachrichten.deSwedish Orphan Biovitrum AB: Sobi to share new clinical data and research at EULAR 2025May 28, 2025 | finanznachrichten.deWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.June 22, 2025 | Crypto Swap Profits (Ad)Berenberg cuts SOBI stock target to SEK360, maintains buyApril 18, 2025 | uk.investing.comRBC Capital Remains a Buy on Swedish Orphan Biovitrum AB (0MTD)January 14, 2025 | markets.businessinsider.comSobi Announces FDA Acceptance of New Drug Application for Avatrombopag (DOPTELET®) for the Treatment of Pediatric Immune ThrombocytopeniaDecember 12, 2024 | markets.businessinsider.comSobi North America Says SNDA Accepted For Avatrombopag In Paediatric Immune ThrombocytopeniaDecember 12, 2024 | markets.businessinsider.comSobi to present new data across its immunology portfolio at the ACR Convergence 2024November 7, 2024 | finance.yahoo.comSee More Headlines SWTUY Stock Analysis - Frequently Asked Questions How have SWTUY shares performed this year? SWEDISH ORPHAN/S's stock was trading at $24.38 at the beginning of 2025. Since then, SWTUY stock has increased by 0.0% and is now trading at $24.38. View the best growth stocks for 2025 here. How do I buy shares of SWEDISH ORPHAN/S? Shares of SWTUY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private Households Sub-IndustryN/A Current SymbolOTCMKTS:SWTUY Previous SymbolNASDAQ:SWTUY CIKN/A Webwww.sobi.com Phone46-0-869-720-00FaxN/AEmployees902Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.50 Trailing P/E Ratio48.76 Forward P/E RatioN/A P/E Growth1.3Net Income$134.73 million Net Margins25.75% Pretax MarginN/A Return on Equity29.63% Return on Assets18.74% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$763.19 million Price / Sales8.71 Cash Flow$0.70 per share Price / Cash Flow34.66 Book Value$2.88 per share Price / Book8.47Miscellaneous Outstanding Shares272,508,000Free FloatN/AMarket Cap$6.64 billion OptionableNot Optionable Beta1.81 Social Links 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (OTCMKTS:SWTUY) was last updated on 6/22/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Biggest Story of My Decade-Long Career in Silicon ValleySteve Jobs' Lost 'Product' Could Save Tesla On July 21st, a revolutionary announcement could transform Tesl...InvestorPlace | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredYour Guide to Outperforming the Market - Guaranteed.Join the Dream Team and see how we can guarantee stock market wins Credentials are a good thing, especiall...Zacks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SWEDISH ORPHAN/S Please log in to your account or sign up in order to add this asset to your watchlist. Share SWEDISH ORPHAN/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.